Inhaled Angiopoietin‐Like 4 Antisense Oligonucleotide Therapy for Lung Injury and Fibrosis
Advanced Science · 2026-04 · 13 (23)
DOI: 10.1002/advs.202501909 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 23.03.2026. Verfasst von Haiyang Fan und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology, The Seventh Affiliated Hospital, Sun Yat-Sen University, Shenzhen, P. R. China. Hauptthemen laut MEDLINE: Oligonucleotides, Antisense, Angiopoietin-Like Protein 4, Lung Injury, Pulmonary Fibrosis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Key Technologies Research and Development Program, National Natural Science Foundation of China, Natural Science Foundation of Guangdong Province.
Abstract (Originalsprache)
Pulmonary infections and fibrosis remain difficult to treat because current interventions target isolated pathways rather than the coupled axes of inflammation, barrier integrity, and tissue remodeling. Here, it is shown that inhalationally delivered, lung‐targeted antisense oligonucleotides against angiopoietin‐like 4 ( Angptl4 ‐ASO) attenuate both infectious and fibrotic lung disease. In murine models of bacterial and viral pneumonia, Angptl4 ‐ASO reduces inflammatory cell infiltration, preserves alveolar architecture, and improves host defence. In bleomycin‐induced fibrosis, treatment lowered Ashcroft scores, collagen deposition, and α‐smooth muscle actin (SMA) expression, indicating broad efficacy across acute and chronic injury. Comparative transcriptomics reveal model‐specific responses, immune and oxidative‐stress programs in pneumonia versus extracellular matrix (ECM)‐remodeling pathways in fibrosis, yet nearly half of all changes converge on a shared ANGPTL4‐regulated network linking hypoxic, inflammatory, apoptotic, and stress response programs. This conserved signature suggests that ANGPTL4 functions as a central regulator of injury resolution regardless of the initiating insult. Mechanistically, Angptl4 ‐ASO reinforced epithelial barrier integrity through coordinated regulation of tight junction and glycoprotein pathways. Longitudinal tracking of a Sulfo‐Cyanine 5 (Cy5)‐conjugated Angptl4 ‐ASO confirmed a lung‐retentive biodistribution, with sustained intrapulmonary localization and minimal systemic dissemination over a 144‐hour window. Collectively, these findings position inhaled ANGPTL4‐ASO as a host‐directed, multi‐axis therapeutic strategy that addresses shared and context‐specific drivers of diverse pulmonary pathologies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Otolaryngology, The Seventh Affiliated Hospital, Sun Yat-Sen University, Shenzhen, P. R. China.
- Department of Thoracic Surgery, The Seventh Affiliated Hospital, Sun Yat-Sen University, Shenzhen, P. R. China.
- Joint Laboratory of Guangdong-Hong Kong Universities for Vascular Homeostasis and Diseases, Department of Pharmacology, School of Medicine, Southern University of Science and Technology, Shenzhen, P. R. China.
- Department of Pharmacy, Shenzhen Children's Hospital, Shenzhen, Guangdong Province, 518026, P. R. China.
- Shenzhen Center for Disease Control and Prevention, Shenzhen, 518055, P. R. China.
- Lee Kong Chian School of Medicine, Nanyang Technological University Singapore, 11 Mandalay Road, Singapore, 308232, Singapore.
ORCID-Profile: Damien Chua, Hong Sheng Cheng, Liang Li
Förderung
- Key Technologies Research and Development Program
- National Natural Science Foundation of China
- Natural Science Foundation of Guangdong Province
- Shenzhen Science and Technology Innovation Program
- Lee Kong Chian School of Medicine, Nanyang Technological University
- Southern University of Science and Technology
Zitieren
APA
Fan, H., Tan, Y., Zhang, J., Liu, X., Qu, J., Chua, D., Cheng, H. S., Kim, J. H. S., Liu, Y. X., Qin, C., Liu, Y., Li, D., Qiu, J., Chi, M., Bi, M., Zhang, Q., Li, Y., Motamedi Joibari, M., Nilsson, S. K., …, & Li, L. (2026). Inhaled Angiopoietin‐Like 4 Antisense Oligonucleotide Therapy for Lung Injury and Fibrosis. Advanced Science, 13(23). https://doi.org/10.1002/advs.202501909
Vancouver
Fan H, Tan Y, Zhang J, Liu X, Qu J, Chua D, et al. Inhaled Angiopoietin‐Like 4 Antisense Oligonucleotide Therapy for Lung Injury and Fibrosis. Advanced Science. 2026;13(23). doi:10.1002/advs.202501909
BibTeX
@article{Fan2026,
author = {Fan, Haiyang and Tan, Yuanyang and Zhang, Junhang and Liu, Xiaoya and Qu, Jing and Chua, Damien and Cheng, Hong Sheng and Kim, Joseph Han Sol and Liu, Yu Xuan and Qin, Changfei and Liu, Yingzi and Li, Dezhi and Qiu, Jikang and Chi, Mengshi and Bi, Mingmin and Zhang, Qiwei and Li, Yun and Motamedi Joibari, Masoumeh and Nilsson, Stefan K and Tan, Nguan Soon and Fan, Yunping and Li, Liang},
title = {Inhaled Angiopoietin‐Like 4 Antisense Oligonucleotide Therapy for Lung Injury and Fibrosis},
journal = {Advanced Science},
year = {2026},
volume = {13},
number = {23},
doi = {10.1002/advs.202501909}
}
EUVIMED